

***Amendments to the Claims***

The listing of claims will replace all prior versions, and listings of claims in the application.

Claims 1-18 (cancelled).

19. (currently amended) ~~A use of estrogenically active substance and a progestogenically active substance in the preparation of a medicament, characterized in that the medicament is for hormone replacement therapy for administration to~~ method of treating a female in need of such hormone replacement therapy, the method comprising administering a medicament comprising a plurality of doses for consecutive administration in alternating phases, which phases consist of a relatively dominant estrogenic activity phase comprising three consecutive daily doses or an equivalent thereof, of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17 $\beta$ -estradiol, and a relatively dominant progestogenic activity phase comprising three daily doses or an equivalent thereof, of a combination of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17 $\beta$ -estradiol and a substance exhibiting progestogenic activity equivalent to about 90  $\mu$ g per day of norgestimate to the female in need of treatment.

Claims 20-28 (cancelled).

29. (currently amended) The method ~~of as claimed in claim~~ [[14]] 19 in which the daily doses in the relatively dominant estrogenic activity phase comprise about 1 mg per day of 17 $\beta$ -estradiol, and in the relatively dominant progestogenic activity phase comprise about 1 mg per day of 17 $\beta$ -estradiol and about 90  $\mu$ g per day of norgestimate.

30. (currently amended) The method ~~as claimed in~~ of claim 29 wherein the doses are in oral form.

31. (currently amended) The method ~~as claimed in~~ of claim 30 wherein the doses are in tablet form.

Claims 32-34 (cancelled).